Other: Standard ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
67	Polycystic kidney disease	3

67. Polycystic kidney disease

---

Clinical trials : 216 /  Drugs : 219 - (DrugBank : 50) / Drug target genes : 39 - Drug target pathways : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00920309 (ClinicalTrials.gov)	June 2009	12/6/2009	Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy	Rapamycin as Treatment for ADPKD: The Role of Biomarkers in Predicting a Response to Therapy	Autosomal Dominant Polycystic Kidney Disease	Drug: Rapamycin;Other: Standard of Care-Placebo	Yale University	NULL	Terminated	18 Years	70 Years	All	21	Phase 2/Phase 3	United States
2	NCT00346918 (ClinicalTrials.gov)	June 2006	22/6/2006	Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Sirolimus (Rapamune®) for Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD): a Randomized Controlled Study.	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Drug: Sirolimus;Other: Standard	University of Zurich	NULL	Completed	18 Years	40 Years	Both	100	Phase 3	Switzerland
3	NCT00283686 (ClinicalTrials.gov)	January 2006	26/1/2006	HALT Progression of Polycystic Kidney Disease Study A	HALT Progression of Polycystic Kidney Disease Study A	Kidney, Polycystic	Drug: Lisinopril;Drug: Telmisartan;Drug: Placebo;Other: Standard Blood Pressure Control;Other: Low Blood Pressure Control	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Boehringer Ingelheim;Merck Sharp & Dohme Corp.;Polycystic Kidney Disease Foundation;University of Pittsburgh;Washington University School of Medicine	Completed	15 Years	64 Years	All	558	Phase 3	United States